HOME >> MEDICINE >> NEWS
CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome

London, United Kingdom, Monday 6 September 2004. New data from the first international prospective study of statin treatment in people with the metabolic syndrome demonstrate that CRESTORTM (rosuvastatin) achieves excellent results in lowering LDL-cholesterol (LDL-C) and raising HDL-C in this important and growing patient population.1 Today's results from the COMETS study, presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany, show that CRESTOR 10mg lowers LDL-C and raises HDL-C significantly more than atorvastatin 10mg in patients with the metabolic syndrome and raised LDL-C.1

People with the metabolic syndrome, which affects nearly one in five men and nearly one in four women, are nearly twice as likely to die from cardiovascular disease and their risk of heart attack and stroke is threefold.2 ,3 The term 'metabolic syndrome' describes a clustering of three or more cardiovascular risk factors, including abdominal obesity, elevated triglycerides, low HDL-C (or 'good' cholesterol), hypertension and elevated blood glucose.4 For these 'high risk' patients, lowering LDL-C levels is the primary lipid treatment target to reduce their cardiovascular risk, as highlighted in both the US National Cholesterol Education Programme's Adult Treatment Panel III (US NCEP ATP III) guidelines and the recently revised European Guidelines on Cardiovascular Disease Prevention in Clinical Practice.4-6 Sub-group analyses of long-term studies have also shown that statin treatment in people with the metabolic syndrome can reduce cardiovascular events.7,8

The COMETS study, part of the GALAXY ProgrammeTM, assessed both the effect of CRESTOR 10mg compared to atorvastatin 10mg and placebo at six weeks and, following titration, CRESTOR 20mg and atorvastatin 20mg at 12 weeks. The results in 397 patients with the metabolic syndrome (
'"/>

Contact: Rachael Wood
rachael.wood@astrazeneca.com
44-162-551-9514
Shire Health International
6-Sep-2004


Page: 1 2 3 4

Related medicine news :

1. 1st data show CRESTOR highly effective at lowering LDL-C in patients with type 2 diabetes
2. CRESTOR (TM) improves apolipoprotein and lipid ratios - markers of cardiovascular disease risk
3. Corrected metabolism leads to health benefits and weight loss
4. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
5. Lack of specific collagen type leads to osteoarthritis
6. UCI study uncovers how plaque in neck artery leads to stroke-inducing blood clots
7. Vaginal hysterectomy leads to better outcomes than abdominal surgery
8. Little evidence that breast cancer diagnosis leads to employment discrimination, study concludes
9. Marine sponge leads researchers to immune system regulator
10. Safer drug prescribing for seniors in nursing homes: Canada leads the way
11. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist Dr. John ... have never imagined back in 1991 that this journey would have taken me into ... last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more ... CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a more ... with fewer resources. It highlights the business’ principles, research and collaboration efforts in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, ... the first in a new class of photodynamic cosmetics (PDC). , Allumera® is ... visibly reduce outward signs of aging, and minimize the appearance of pores – ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... VANCOUVER , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) ... the Bloom Burton & Co. Healthcare Investor Conference 2017 at the ... Edward Wright , Chief Executive Officer of the Company is ... Company,s CFO, Richard Bear and the Chairman of the ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
Breaking Medicine Technology:
Cached News: